Anthony Barron is moderating an “Issue Panel” on Comprehensive Genomic Profiling (CGP).
For more information on this event, click here.
What impact does disease rarity have on rare and orphan drug pricing?
As more pharmaceutical companies develop and launch drugs to treat rare diseases, reimbursement decisions indicate that payers are looking at a range of...